SIGA Technologies Inc(SIGA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 4:00 PM ET (Korea 10/30 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.04 | Insider Own | 42.76% | Shs Outstand | 71.8M | Perf Week | 0.95% |
| Market Cap | 0.23B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 41.1M | Perf Month | -6.47% |
| Enterprise Value | 0.11B | PEG | - | EPS next Q | - | Inst Own | 48.78% | Short Float | 8.66% | Perf Quarter | -2.75% |
| Income | -0.00B | P/S | 4.26 | EPS this Y | - | Inst Trans | 0.54% | Short Ratio | 5.64 | Perf Half Y | -30.87% |
| Sales | 0.05B | P/B | 1.38 | EPS next 5Y | - | ROA | -1.36% | Short Interest | 3.56M | Perf YTD | -41.17% |
| Book/sh | 2.3 | P/C | 1.94 | EPS past 3/5Y | -10.75% -14.51% | ROE | -1.49% | 52W High | -57.51% ($7.48) | Perf Year | -55.78% |
| Cash/sh | 1.64 | P/FCF | - | Sales past 3/5Y | -5.13% -5.42% | ROIC | -1.69% | 52W Low | 12.37% ($2.83) | Perf 3Y | -14.42% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -103.41% | Gross Margin | 54.35% | Volatility(W/M) | 4.47% 4.14% | Perf 5Y | -31.91% |
| Dividend TTM | - | EV/Sales | 2.07 | Sales Y/Y TTM | -70.13% | Oper. Margin | -20.76% | ATR (14) | 0.13 | Perf 10Y | 115.31% |
| Dividend Ex-Date | 2026/4/7 | Quick Ratio | 16.48 | EPS Q/Q | -64.94% | Profit Margin | -5.19% | RSI (14) | 48.63 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 21.72 | Sales Q/Q | -49.45% | SMA20 | -0.93% ($3.21) | Beta | 1.09 | Target Price | $11.57 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/6 | SMA50 | -0.11% ($3.18) | Rel Volume | 0.78 | Prev Close | $3.31 |
| Employees | 49 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -24.32% ($4.2) | Avg Volume(3M) | 0.63M | Price | $3.18 |
| IPO | 1997/9/9 | Option/Short | Yes/Yes | Trades | 2245 | Volume | 495,011 | Change | -3.93% |
SIGA Technologies is a U.S. biodefense company developing antiviral treatments targeting high-risk pathogens such as smallpox and mpox (monkeypox). Centered on its core product TPOXX—an antiviral therapy available in both oral and intravenous formulations—the company operates a public health security-focused business model, generating revenue through U.S. government stockpiling contracts and procurement agreements with foreign governments.
Over the past 1 year, on the lower side
57% below its 1-year high.
Traded less than usual. That is 78% of its average volume.
SIGA has a sound balance sheet but weak earning power
Of every $100 in sales, $20.76 is lost.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $426. Peers typically go for $211. Compared with its own 4-year average, it is 60% pricier now.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -31.9%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 48.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #49 of 83 in the industry
Based on market cap of $228M.
BIOA#46 BioAge Labs Inc $273M PER - 
ACB#47 Aurora Cannabis Inc $268M PER - 
LFCR#48 Lifecore Biomedical Inc $247M PER - SIGA#49 SIGA Technologies Inc $228M PER - 
AKBA#50 Akebia Therapeutics Inc $206M PER - 
FAQ
What kind of company is SIGA?
SIGA belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of SIGA?
The market cap of SIGA is approximately $228M, ranking 3,922 within its sector.
What is the 52-week high and low for SIGA?
SIGA has recorded a 52-week high of $7.48 and a low of $2.83.
